SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Immunofluorescence microscopy MCF10A cells were grown on glass coverslip pre-coated with polylysine. To induce DNA damage repair foci the cells were treated with 0.5mM BMN673 for 4 or 8 hours. Cells were fixed with 4% paraformaldehyde in PBS for 10 min, permeablized with 0.3% Triton for 10 min, and blocked with 3% BSA in PBS for 40 min at room temperature. Cells were then incubated with antibodies against gH2AX (JBW301, Upstate) or RAD51 (SC-8349, Santa Cruz) at 4°C overnight, followed by the incubation with species-specific Alexa488 or Alexa647-conjugated secondary antibodies (Thermofisher) for 1hr at room temperature. Coverslips were mounted on the slides in Vectashield containing DAPI for nuclear counterstain. Images were acquired with a confocal microscope (Zeiss LSM 780) equipped with a 63x
water immersion objective and a CCD camera, using the ZEN software. Automated foci counting was done using the Foci Counter (The Bioimaging Center, University of Konstanz) plugin in ImageJ. At least 150 cells were scored for each experiment, and each experiment was repeated three times.
siRNA transfection
SMARTpool ON-TARGETplus siRNAs targeting BRCA1(L-003461-00-0005), ARID1A (L-017263-00-0005), GPBP1 (L-014236-02-0005) and non-targeting control siNT4 were purchased from GE Dharmacon. siRNAs were transfected into cells using Lipofectamine RNAiMax transfection reagent (ThermoFisher) according to the manufacturer's instruction. The cells were transfected in 384-well plates at a final siRNA concentration of 20nM. After an initial 24h period of gene knockdown, drug sensitivity was determined by adding the indicated drugs for 72h.
Drug combination screening
Cells were seeded onto 384-well plates (1,000 cells/well) 18 hours prior to treatment with drug either singly or in combination with another drug. A pair of drugs is combined in a series of one DMSO and five or seven concentrations centered on the IC50 dose, resulting in a 6 × 8 escalating combination dose matrix using a robotic liquid handler. After a 72 hour drug treatment, cell proliferation was determined by staining with Hoescht 33342 (5ug/ml) and cell number counted using a Thermo CellInsight High Content microscope. Synergistic effects between different drug combos was measured by determination of synergy score using comparison to Loewe additive model with Chalice Analyzer (Zalicus Inc. Cambridge, MA). Combination Index values were calculated using CompuSyn (www.compusyn.com).
Cell line drug sensitivity prediction
A total of 568 genes were mapped between the chemical-genetic interaction map and gene expression data obtained from (https://portals.broadinstitute.org/ccle/home). Expression data was normalized to a median of 0 across cell lines. Sensitivity for each drug was defined by its area under the curve, or AUC (Basu et al., 2013) . To predict the sensitivity of a given cell line for a particular drug in an unsupervised fashion, the sign of the chemical-genetic interaction score for each gene in the map was multiplied by the normalized expression of that gene and this product summed over all genes in the map. Hence, for each cell line the predicted AUC for drug d (pAUCd) is:
Where G is the set of all genes in the map for drug d, sgd is the score of drug d with gene g and eg is the normalized expression of g in this cell line. This procedure rewards for cases where the expression and interaction scores are consistent, i.e. when both expression and score is negative or both expression and score are positive, and in both these cases will predict drug sensitivity. This procedure was performed at differing cutoffs of the interaction map based on the absolute value of the score. For each drug a pAUC was computed for each cell line and this value was then correlated with the published AUC.
Reverse transcription PCR (RT-qPCR)
2.5 mg of total RNA was reverse transcribed using murine Moloney leukemia virus (MMLV) reverse transcriptase, with oligo dT and template switching oligos as primers for cDNA synthesis. Real-time PCR with SYBR green detection was performed using an ABI Prism 7700 thermocycler (Applied Biosystem).
The house keeping genes HPRT-1 and b2M was used as control for normalization. A ∆∆Cq method was used to process the data for the target gene (GPBP1) to calculate relative gene expression normalized to house keeping genes.
RNAseq analysis
RNA extraction from MCF10A cells was performed with RNeasy mini kit (Qiagen). The samples were treated sequentially with Baseline-ZERO DNase and Ribo-ZERO RNA removal kit (Epicentre) to deplete DNA and rRNA. 35ng of rRNA-depleted sample was used as input for library preparation using ScriptSeq were analyzed using FASTQC for quality control and adapters were filtered using cutadapt (Martin, 2017) . The filtered raw reads were pseudoaligned and quantification of the transcripts was performed with Kallisto (Bray et al., 2016) using GRC38 reference human transcriptome. Transcript abundance estimates were converted to gene level estimates using an R package Tximport (Soneson et al., 2015) .
Differential expression analysis between sets of conditions was performed using DESeq2 and averaged over both replicates (Anders and Huber, 2010) . Analysis of the enrichment of functional gene groups and pathways among differentially expressed genes was performed using gene-set enrichment analysis (GSEA) (Subramanian et al., 2005) . Enrichment plots were calculated based on ranking of differentially expressed genes between different conditions. RNA-seq data are available under GEO:GSE101904
(https://www.ncbi.nlm.nih.gov/geo/).
Clinical trial data analysis
Tumor samples were tested for mutations in a panel of 322 genes using FoundationOne test from Foundation Medicine (Waltham, MA). In the ARIEL-2 trial (NCT01891344) 154 patients were selected that were wild type in HR pathways genes including BRCA1, BRCA2 and CDK12. Clinical characteristics were taken from Swisher et al (Swisher et al., 2017) . ARIEL-2 was approved by the institutional review board at each study site and was done in accordance with the Declaration of Helsinki and Good Clinical
Practice Guidelines of the International Conference on Harmonisation. Patients provided written informed consent before participation.
Statistical analysis
All error bars are s.d. unless otherwise noted. All P-values based on two-tailed t-test.
